Menu
Search
|

Menu

Close
X

Ionis Pharmaceuticals Inc IONS.OQ (NASDAQ Stock Exchange Global Select Market)

51.03 USD
+1.15 (+2.31%)
As of Feb 23
chart
Previous Close 49.88
Open 50.22
Volume 198,957
3m Avg Volume 381,622
Today’s High 51.05
Today’s Low 49.45
52 Week High 65.51
52 Week Low 37.27
Shares Outstanding (mil) 124.80
Market Capitalization (mil) 6,368.31
Forward P/E 357.68
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.79 Mean rating from 14 analysts

KEY STATS

Revenue (mm, USD)
FY17
335
FY16
347
FY15
284
EPS (USD)
FY17
-0.070
FY16
-0.720
FY15
-0.746
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
357.68
33.62
Price to Sales (TTM)
vs sector
12.85
8.35
Price to Book (MRQ)
vs sector
20.65
5.22
Price to Cash Flow (TTM)
vs sector
278.64
25.88
Total Debt to Equity (MRQ)
vs sector
194.06
15.84
LT Debt to Equity (MRQ)
vs sector
194.04
12.39
Return on Investment (TTM)
vs sector
1.54
13.63
Return on Equity (TTM)
vs sector
7.66
15.39

EXECUTIVE LEADERSHIP

Stanley Crooke
Chairman of the Board, President, Chief Executive Officer, Since 1991
Salary: $824,535.00
Bonus: $1,205,880.00
Elizabeth Hougen
Chief Financial Officer, Senior Vice President - Finance, Since 2013
Salary: $412,839.00
Bonus: $297,244.00
B. Lynne Parshall
Chief Operating Officer, Corporate Secretary, Director, Since 2013
Salary: $712,676.00
Bonus: $801,761.00
Patrick O'Neil
Senior Vice President, Legal, General Counsel, Chief Compliance Officer and Corporate Secretary, Since 2016
Salary: $440,777.00
Bonus: $317,359.00
C. Frank Bennett
Senior Vice President - Antisense Research, Since 2006
Salary: $397,077.00
Bonus: $234,524.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

2855 Gazelle Ct
CARLSBAD   CA   92010-6670

Phone: +1760.9319200

Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company's segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners. The Akcea Therapeutics segment includes the operations of the Company's subsidiary, Akcea Therapeutics, Inc. (Akcea Therapeutics). Akcea Therapeutics is focused on developing and commercializing volanesorsen and other clinical-stage drugs for serious cardiometabolic diseases caused by lipid disorders. The Company is developing volanesorsen to treat two severe and rare, genetically defined diseases, familial chylomicronemia (FCS) and familial partial lipodystrophy (FPL). The Company offers SPINRAZA, a Generation 2.0+ antisense drug.

SPONSORED STORIES